Search PubMed⌕ Search

Biomedical subjects

E Israel

Publications and source records attributed to E Israel.

At least 163 records · Page 9Linked to original sources
PubMed1976

Antigenic properties of subsets of splenic T lymphocytes responding to lectins.

The aim of the present study was to characterize the antigenic properties of spleen cells responding in vitro to various mitogenic stimuli. Mouse spleen cells were treated with alloantibodies and C and then cultured with various concentrations of lectins. The exposure of spleen cells to various dilutions of either anti-theta serum and C or anti-Ly serum and C inhibited the response to optimal concentrations of PHA to a greater extent than the response to optimal concentrations of Con A. With the exception of the optimal lectin concentration, theta-antiserum and C had a stronger inhibitory effect on the response to Con A than to PHA. The exposure of spleen cells to H-2 antiserum and C inhibited their response to Con A to a greater extent than to PHA. The inhibitory activity of H-2 antiserum and C was inversely correlated with the dose of PHA used for stimulation. The lower the concentration of PHA used for stimulation the more effective was the inhibitory effect of the antiserum. The inhibitory effect of H-2 antiserum and C on the response to Con A was highest at optimal concentrations of the mitogen, and somewhat less pronounced above or below this concentration. The present study suggests that subsets of splenic T-cells that react to various concentrations of mitogens, differ in their theta- and H-2 alloantigenicity.

Animals↗
PubMed1975

The nature and function of T-cell antigens.

T-lymphocytes differ antigenically from B-lymphocytes. In the present study attempts were made to determine the role of surface antigens of T-cells, in their migration in vivo and in their response to mitogens. Exposure of thymus cells to anti-H2 sera inhibits migration to the lymph nodes (LN) to a greater extent than to the spleen. Fab fragments of H-2 antisera had only a slight effect on lymphocyte migration, inhibiting the LN-seeking stream only slightly more than the spleen-seeking stream. The interaction of Con-A with carbohydrates on the cell-surface of lymphocytes inhibits preferentially their localization in LN. Studies on the migration of lymphocytes that had localized either in the LN or spleens of primary host indicate that Con-A does not eliminate LN-seeking cells, but rather inhibits their active localization in LN. The subpopulation of lymphocytes, in both thymus and spleen that responds to Con-A was found to possess a higher H-2 antigenicity and a lower Ly and theta-antigenicity than the cells responding to PHA. Spleen cells responding to low concentrations of PHA had a relatively high H-2 antigenicity, whereas thos responding to high concentrations of PHA had a low H-2 antigenicity. Exposure of thymus cells to H-2 antiserum alone markedly inhibited their response to Con-A. Similar treatment of spleen cells had only a weak inhibitory effect.

Animals↗
PubMed1972

[Anencephalus].

Explore the source record for details and available documents.

Africa↗
PubMedDate not supplied

Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial.

CONTEXT: Long-acting beta(2)-agonists are prescribed for patients with persistent asthma and are sometimes used without inhaled corticosteroids (ICSs). No evidence exists, however, to support their use as monotherapy in adults with persistent asthma. OBJECTIVE: To examine the effectiveness of salmeterol xinafoate, a long-acting beta(2)-agonist, as replacement therapy in patients whose asthma is well controlled by low-dose triamcinolone acetonide, an ICS. DESIGN AND SETTING: A 28-week, randomized, blinded, placebo-controlled, parallel group trial conducted at 6 National Institutes of Health-sponsored, university-based ambulatory care centers from February 1997 to January 1999. PARTICIPANTS: One hundred sixty-four patients aged 12 through 65 years with persistent asthma that was well controlled during a 6-week run-in period of treatment with inhaled triamcinolone (400 microg twice per day). INTERVENTIONS: Patients were randomly assigned to continue triamcinolone therapy (400 microg twice per day; n = 54) or switch to salmeterol (42 microg twice per day; n = 54) or to placebo (n = 56) for 16 weeks, after which all patients received placebo for an additional 6-week run-out period. MAIN OUTCOME MEASURES: Change in morning and evening peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV(1)), self-assessed asthma symptom scores, rescue albuterol use, asthma-specific quality-of-life scores, treatment failure, asthma exacerbation, bronchial reactivity, and markers of airway inflammation, compared among the 3 treatment groups. RESULTS: During the 16-week randomized treatment period, no significant differences between the salmeterol and triamcinolone groups were observed for conventional outcomes of clinical studies of asthma therapy-morning PEF, evening PEF, asthma symptom scores, rescue albuterol sulfate use, or quality of life. Both active treatments were superior to placebo. However, the salmeterol group had more treatment failures than the triamcinolone group (13/54 [24%] vs 3/54 [6%]; P =.004), as well as more asthma exacerbations (11/54 [20%] vs 4/54 [7%]; P =.04), greater increases in median (interquartile range) sputum eosinophils (2.4% [0.0% to 10.6%] vs -0.1% [-0.7% to 0.3%]; P<.001), eosinophil cationic protein (71 [-2 to 430] U/L vs -4 [-31 to 56] U/L; P =.005), and tryptase (3.1 [2.1 to 7.6] ng/mL vs 0.0 [0.0 to 0.7] ng/mL; P<.001). The duration of benefit when patients were switched from active treatment to placebo after 22 weeks of randomized treatment was not significantly longer in the triamcinolone group than in the salmeterol group. CONCLUSIONS: Patients with persistent asthma well controlled by low doses of triamcinolone cannot be switched to salmeterol monotherapy without risk of clinically significant loss of asthma control.

Administration, Inhalation↗
PubMedDate not supplied

Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial.

CONTEXT: Inhaled long-acting beta(2)-agonists improve asthma control when added to inhaled corticosteroid (ICS) therapy. OBJECTIVE: To determine whether ICS therapy can be reduced or eliminated in patients with persistent asthma after adding a long-acting beta(2)-agonist to their treatment regimen. DESIGN AND SETTING: A 24-week randomized, controlled, blinded, double-dummy, parallel-group trial conducted at 6 National Institutes of Health-sponsored, university-based ambulatory care centers from February 1997 through January 1999. PARTICIPANTS: One hundred seventy-five patients aged 12 through 65 years with persistent asthma that was suboptimally controlled during a 6-week run-in period of treatment with inhaled triamcinolone acetonide (400 microg twice per day). INTERVENTION: Patients continued triamcinolone therapy and were randomly assigned to receive add-on therapy with either placebo (placebo-minus group, n = 21) or salmeterol xinafoate, 42 microg twice per day (n = 154) for 2 weeks. The entire placebo-minus group was assigned and half of the salmeterol group (salmeterol-minus group) was randomly assigned to reduce by 50% (for 8 weeks) then eliminate (for 8 weeks) triamcinolone treatment. The other half of the salmeterol group (salmeterol-plus group) was randomly assigned to continue both salmeterol and triamcinolone for the remaining 16 weeks (active control group). MAIN OUTCOME MEASURE: Time to asthma treatment failure in patients receiving salmeterol. RESULTS: Treatment failure occurred in 8.3% (95% confidence interval [CI], 2%-15%) of the salmeterol-minus group 8 weeks after triamcinolone treatment was reduced compared with 2.8% (95% CI, 0%-7%) of the salmeterol-plus group during the same period. Treatment failure occurred in 46.3% (95% CI, 34%-59%) of the salmeterol-minus group 8 weeks after triamcinolone therapy was eliminated compared with 13.7% (95% CI, 5%-22%) of the salmeterol-plus group. The relative risk (95% CI) of treatment failure at the end of the triamcinolone elimination phase in the salmeterol-minus group was 4.3 (2.0-9.2) compared with the salmeterol-plus group (P<.001). CONCLUSIONS: Our results indicate that in patients with persistent asthma suboptimally controlled by triamcinolone therapy alone but whose asthma symptoms improve after addition of salmeterol, a substantial reduction (50%) in triamcinolone dose can occur without a significant loss of asthma control. However, total elimination of triamcinolone therapy results in a significant deterioration in asthma control and, therefore, cannot be recommended.

Administration, Inhalation↗
PubMedDate not supplied

Closing of the nurse-midwifery service at Boston City Hospital. What were the issues involved?

This article describes the experiences of 11 staff CNMs practicing in an inner-city hospital serving low-income women. A history of the conflicts between the OB/GYN Department and the Midwifery Service at Boston City Hospital is presented, as well as an overview of events in 1987-88 that resulted in the unanimous resignation of the staff CNMs and the closing of the service. Discussion of the issues is presented, as well as implications for midwifery practice.

Authoritarianism↗
PubMedDate not supplied

Dysgonic fermenter-2: a clinico-epidemiologic review.

In the literature to date, there have been 44 confirmed cases of infection with the Dysgonic Fermenter-2 (DF-2) bacterium. DF-2 infections appear to demonstrate a strong association with dog bites (or recent exposure to dogs) and have a predilection for patients with defective host defenses although immunocompetent individuals are also susceptible. Recently, the first two cases of documented DF-2 infection following cat bite have been reported. Of the cases reported, 42 of the 44 blood cultures grew DF-2. In one of the two cases where blood culture failed to grow DF-2, the bacterium was isolated at the time of operation from an infected myxoma of the tricuspid valve. In the other case, the organism was isolated from the eyelid margin of a case of angular blepharitis. Peripheral blood smears also afford an effective and practical clinical tool for early diagnosis; 9 of 10 patients for whom smears were done tested positive. This paper reviews the epidemiologic, microbiological, and clinical features of this relatively new illness and also offers general guidelines to physicians for clinical management. Health professionals, especially those providing care for high risk groups, should be alerted to this potentially fatal infection.

Adolescent↗